Journey Medical (DERM) Stock: Buy, Sell, or Hold?
DERM - Journey Medical Corporation Common Stock
$6.72
-0.12 (-1.75%)
▼
5d:
+6.33%
30d:
-11.23%
90d:
-5.22%
HOLD
LOW Confidence
Analysis Updated: Oct 1, 2026 12:00 AM ET
Earnings: Nov 11, 2026
Get Alerted When DERM Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: DERM shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
📊 HOLD: DERM shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$15.28
Based on 7.0% avg growth
INTRINSIC VALUE TODAY
$9.49
29.2% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 16.1x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: DERM is currently trading at $6.72, which is considered oversold relative to its 30-day fair value range of $6.74 to $7.74. From a valuation perspective, the stock is trading at a discount (Forward PE: 9.9) compared to its historical average (16.1). Remarkably, the market is currently pricing in an annual earnings decline of 15.0% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, DERM is in a uptrend. Immediate support is located at $6.08, while resistance sits at $7.61.
Market Sentiment: DERM scores 65/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. In the options market, Implied Volatility is low (22th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $13.75 (+104.6%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, DERM is in a uptrend. Immediate support is located at $6.08, while resistance sits at $7.61.
Market Sentiment: DERM scores 65/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. In the options market, Implied Volatility is low (22th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $13.75 (+104.6%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$6.74 -
$7.74
Company Quality Score
61/100
(BUY)
Options IV Signal
22th percentile
(COMPLACENCY WARNING)
Volume Confirmation
HIGH
Confidence Score
92.3%
All Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Options cheap (IV 22th percentile)
- BULLISH: Strong technical setup (65/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 104.6% below Wall St target ($13.75)
- CAUTION: Bottoming setup, but lagging the sector by 26% over 20 days — wait for relative strength
Trading Range Analysis
30-Day Trading Range
$6.74 -
$7.74
Current vs Trading Range
OVERSOLD
Expected Move (7 Days)
±$0.62
(9.3%)
Support & Resistance Levels
Support Level
$6.08
Resistance Level
$7.61
Current Trend
Uptrend
Technical data as of
Oct 1, 2026
Fundamental Context
Forward P/E (Next Year Est.)
9.92
Wall Street Target
$13.75
(+104.6%)
Revenue Growth (YoY)
23.3%
Profit Margin
-8.9%
Valuation Discount vs History
-15.0% cheaper
PE vs Historical
9.9 vs 16.1
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-15.0%
(market-implied from PE analysis)
1-Year Target
$6.05
(-10%)
2-Year Target
$5.44
(-19%)
3-Year Target
$4.90
(-27%)
3-Yr Target (if PE normalizes)
(PE: 10→16)
$7.95
(+18%)
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 9.9 to 16.1
Stabilization Target:
$10.91
(+62.3%)
PE Expansion Potential:
+62.3%
Share & Embed Analysis
Last updated: October 01, 2026 10:59 PM ET
Data refreshes hourly during market hours. Next update: 11:59 PM
Data refreshes hourly during market hours. Next update: 11:59 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is DERM showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences I… |
STRONG BUY
25 analysts |
$208 | 54 HOLD |
|
ZTS
Zoetis Inc |
BUY
20 analysts |
$96 | 58 HOLD |
|
LNTH
Lantheus Holdings Inc |
STRONG BUY
13 analysts |
$108 | 55 HOLD |
|
AQST
Aquestive Therapeutics I… |
STRONG BUY
9 analysts |
$9 | 62 BUY |
|
BCRX
BioCryst Pharmaceuticals… |
STRONG BUY
12 analysts |
$21 | 53 HOLD |
